Intra Cellular Therapies Valuation

Intra Cellular Investor Information

About 96.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.73. Intra Cellular Therapies had not issued any dividends in recent years. Based on the analysis of Intra Cellular's profitability, liquidity, and operating efficiency, Intra Cellular Therapies is not in a good financial situation at the moment. It has a very high risk of going through financial straits in August.

Intra Cellular Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Intra Cellular has an asset utilization ratio of 49.81 percent. This signifies that the Company is making $0.5 for each dollar of assets. An increasing asset utilization means that Intra Cellular Therapies is more efficient with each dollar of assets it utilizes for everyday operations.

Intra Cellular Ownership Allocation

Intra Cellular Therapies has a total of 106.52 Million outstanding shares. The majority of Intra Cellular Therapies outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intra Cellular to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intra Cellular Therapies. Please pay attention to any change in the institutional holdings of Intra Cellular Therapies as this could imply that something significant has changed or is about to change at the company. On May 14, 2025, Representative Josh Gottheimer of US Congress acquired under $15k worth of Intra Cellular Therapies's common stock.

Intra Cellular Profitability Analysis

The company reported the previous year's revenue of 680.85 M. Net Loss for the year was (74.68 M) with profit before overhead, payroll, taxes, and interest of 387.77 M.

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.